MONOCLONAL ANTIBODY-BASED THERAPEUTICS FOR TARGETING MMPS AND DIABETIC NEUROPATHY

$1,430,600FY2021Defense Health AgencyDOD

University Of Texas Health Science Center At Houston

Investigators